bax, but not bcl-2, influences the prognosis of human pancreatic cancer

Gut

Volumn 43, Issue 3, 1998, Pages 414-421

  Friess, H ^a   Lu, Z ^a   Graber, H U ^a   Zimmermann, A ^b   Adler, G ^c   Korc, M ^d   Schmid, R M ^c   Buchler M W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Immunohistochemistry; In situ hybridisation; Northern blot analysis; Pancreatic cancer

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031715838     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.3.414     Document Type: Article

References (40)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Büchler M, Friess H, Schultheiss KH, et al. A randomized controlled trial of adjuvant immuno-therapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer. Cancer 1991;68:1507-12.
3. Friess H, Büchler M, Krüger M, et al. Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin. Pancreas 1992;7:516-21.
4. Korc M, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
5. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
6. Lemoine NR, Lobreseo M, Leung H, et al. The erbB-3 gene in human pancreatic cancer. J Pathol 1992;168:269-73.
7. Yamanaka Y, Friess H, Büchler M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-96.
8. Friess H, Berberat P, Schilling M, et al. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996;74:35-42.
9. Wyllie FS, Dawson T, Bond JA, et al. Correlated abnormalities of transforming growth factor-beta response and p53 expression in thyroid epithelial cell transformation. Mol Cell Endocrinol 1991;76:13-21.
10. Casey G, Yamanaka Y, Friess H, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:51-60.
11. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988;7:123-31.
12. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
13. McDonnell TJ, Deane K, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57:79-88.
14. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992;80:879-86.
15. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
16. Korsmeyer SJ, Shutter JR, Veis DJ, et al. Bcl-2 Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993;4:327-32.
17. Offit K, Wong G, Filippa DA, et al. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991;77:1508-15.
18. Yunis JJ, Mayer MG, Arensen MA, et al. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphomas. N Engl J Med 1989;320:1047-54.
19. Campos L, Roualuit J-P, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993;81:3091-6.
20. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;523:6940-4.
21. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
22. Bargou RC, Daniel PT, Mapara MY, et al. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995;16:854-9.
23. Hermanek P, Sobin LH. TNM classification of malignant tumor. 4th ed. New York: Springer, 1992:71-3.
24. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
25. Riesle E, Friess H, Zhao L, et al. Increased expression of transforming growth factor betas after acute oedematous pancreatitis in rats suggests a role in pancreatic repair. Gut 1997;40:73-9.
26. Gress TM, Müller-Pillasch F, Lerch MM, et al. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62:407-13.
27. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53: 2704-7.
28. Guo XZ, Friess H, Graber HU, et al. Kail expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996;56:4876-80.
29. Graber HU, Müller CF, Vandevelde M. Restricted infection with canine distemper virus leads to down-regulation of myelin gene transcription in cultured oligodendrocytes. Acta Neuropathol (Berl) 1995;90:312-18.
30. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-18.
31. Cox KH, DeLeon DV, Angerer LM, et al. Detection of mRNAs in sea urchin embryos by in situ hybridization using asymmetric RNA probes. Dev Biol 1984;101:485-502.
32. Siegel S. Nonparametric statistics for behavioral science. New York: McGraw-Hill Book Co, 1956.
33. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 1995;75:2209-13.
34. Hellemans P, van Dam PA, Weyler J, et al. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-60.
35. Ofner D, Riehemann K, Maier H, et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995;72:981-5.
36. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329: 690-4.
37. Leek RD, Kaklamanis L, Pezzella F, et al. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69: 135-9.
38. Pilotti S, Collini P, Rilke F, et al. bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-42.
39. Bosari S, Moneghini L, Graziani D, et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995;26:534-40.
40. Sedlak TW, Oltvai ZN, Yang E, et al. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci USA 1995;92:7834-8.